Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome
Open Access
- 9 February 2026
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (2) , 128
Abstract
Introduction: Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) may synergistically enhance early risk stratification of multiple sclerosis (MS) diagnosis after clinically isolated syndromes (CIS). We investigated the prognostic value of combined NfL and GFAP for McDonald 2024 MS diagnosis after CIS and associations with key genetic and environmental risk factors. Methods: CIS participants, within six months after symptom onset, were included in a prospective cohort. We measured baseline serum NfL and GFAP levels and calculated z-scores. We evaluated weighted genetic risk scores for MS susceptibility, HLA-DRB1*15:01 risk and measured Anti-Epstein Barr virus Nuclear Antigen-1 (anti-EBNA1) immunoglobulin G (IgG) antibodies. Associations with MS diagnosis were evaluated using Cox proportional hazards models and time-dependent receiver operating characteristic (ROC) analyses. Results: During follow-up, 162/221 CIS participants were diagnosed with McDonald 2024 MS. Separately, high NfL and GFAP associated with earlier MS diagnoses (hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.12–1.66, p = 0.002, HR 1.12, 95% CI 1.02–1.42, p = 0.01, respectively). In combined models, only NfL remained independently predictive (HR 1.30, 95% CI 1.02–1.60, p = 0.01). Time-dependent ROC analyses showed similar results for NfL alone and combined with GFAP. HLA-DRB1*15:01-risk, but not GFAP or anti-EBNA1 IgG, improved predictive value. Conclusion: Our study found that serum NfL outperformed GFAP in predicting early MS diagnoses after CIS. Baseline NfL, together with HLA-DRB1*15:01 status, provides robust early risk stratification for MS after CIS, whereas GFAP and anti-EBNA1 titres add limited prognostic value. Additional immunological and imaging markers are essential to further refine predictive models.Keywords
Funding Information
- Nationaal MS Fonds (Educational grant P2021-001)
- Nationaal MS Fonds (Project OZ2021-016)
- Stichting MOVES ‘Klimmen tegen MS’ (Inspiratiebeurs)
- Siemens Healthineers
This publication has 50 references indexed in Scilit:
- Class II HLA interactions modulate genetic risk for multiple sclerosisNature Genetics, 2015
- Serum neurofilament light chain levels are increased in patients with a clinically isolated syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2015
- PRSice: Polygenic Risk Score softwareBioinformatics, 2014
- Clinically isolated syndromesThe Lancet Neurology, 2012
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disabilityBrain, 2010
- Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk scoreThe Lancet Neurology, 2009
- Relapses in multiple sclerosis are age- and time-dependentJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and lossJournal of the Neurological Sciences, 2005
- Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficitJournal of the Neurological Sciences, 1995
- A simple salting out procedure for extracting DNA from human nucleated cellsNucleic Acids Research, 1988